| Species |
Human |
| Protein Construction |
TSLPR (Gly25-Lys231)_x000D_
Accession # Q9HC73-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human TSLP (R127A, R130A), His Tag at 2μg/ml(100μl/Well) on the plate can bind TSLPR hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 60-75 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Thymic stromal lymphopoietin (TSLP) is an interleukin-7 (IL-7) like cytokine, which plays an important role in the regulation of immune responses to allergens. TSLP binds to a heterodimeric receptor complex composed of the IL-7 receptor alpha chain (IL-7Ralpha) and the TSLP receptor (TSLPR, also known as CRLF2). |
| Synonyms |
TSLP receptor; TSLPR; CRL2; CRLF2Y; CRLF2; IL-XR; p2RY8/CRLF2 fusion; CRLF2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
